178 related articles for article (PubMed ID: 26194852)
1. Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches.
Ragno R; Ballante F; Pirolli A; Wickersham RB; Patsilinakos A; Hesse S; Perspicace E; Kirsch G
J Comput Aided Mol Des; 2015 Aug; 29(8):757-76. PubMed ID: 26194852
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophore and Docking Guided Virtual Screening Study for Discovery of Type I Inhibitors of VEGFR-2 Kinase.
Bhojwani HR; Joshi UJ
Curr Comput Aided Drug Des; 2017; 13(3):186-207. PubMed ID: 27981900
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR study of tetrahydro-3H-imidazo[4,5-c]pyridine derivatives as VEGFR-2 kinase inhibitors using various charge schemes.
Balupuri A; Balasubramanian PK; Cho SJ
Arch Pharm Res; 2015 Aug; 38(8):1434-42. PubMed ID: 25874606
[TBL] [Abstract][Full Text] [Related]
4. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors.
Zeng H; Zhang H
J Mol Graph Model; 2010 Aug; 29(1):54-71. PubMed ID: 20471293
[TBL] [Abstract][Full Text] [Related]
5. QSAR and molecular docking studies on oxindole derivatives as VEGFR-2 tyrosine kinase inhibitors.
Kang CM; Liu DQ; Zhao XH; Dai YJ; Cheng JG; Lv YT
J Recept Signal Transduct Res; 2016; 36(1):103-9. PubMed ID: 26416217
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.
Sobhy MK; Mowafy S; Lasheen DS; Farag NA; Abouzid KAM
Bioorg Chem; 2019 Aug; 89():102988. PubMed ID: 31146197
[TBL] [Abstract][Full Text] [Related]
7. Exploring QSARs of vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors by MLR, PLS and PC-ANN.
Deeb O; Jawabreh S; Goodarzi M
Curr Pharm Des; 2013; 19(12):2237-44. PubMed ID: 23016841
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
10. A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex--medicinal chemistry consequences of a TKs analysis.
Lintnerová L; García-Caballero M; Gregáň F; Melicherčík M; Quesada AR; Dobiaš J; Lác J; Sališová M; Boháč A
Eur J Med Chem; 2014 Jan; 72():146-59. PubMed ID: 24368209
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
12. Simultaneously optimized support vector regression combined with genetic algorithm for QSAR analysis of KDR/VEGFR-2 inhibitors.
Sun M; Chen J; Cai J; Cao M; Yin S; Ji M
Chem Biol Drug Des; 2010 May; 75(5):494-505. PubMed ID: 20486936
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
[TBL] [Abstract][Full Text] [Related]
14. Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect.
Shi L; Zhou J; Wu J; Shen Y; Li X
Curr Med Chem; 2016; 23(10):1000-40. PubMed ID: 26860998
[TBL] [Abstract][Full Text] [Related]
15. Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review.
Achary PGR
Mini Rev Med Chem; 2020; 20(14):1375-1388. PubMed ID: 32348219
[TBL] [Abstract][Full Text] [Related]
16. Quantitative structure activity relationship and molecular simulations for the exploration of natural potent VEGFR-2 inhibitors: an
Sharma N; Sharma M; Rahman QI; Akhtar S; Muddassir M
J Biomol Struct Dyn; 2021 May; 39(8):2806-2823. PubMed ID: 32363995
[TBL] [Abstract][Full Text] [Related]
17. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
[TBL] [Abstract][Full Text] [Related]
18. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
[TBL] [Abstract][Full Text] [Related]
19. De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction.
Zhang Y; Liu H; Jiao Y; Yuan H; Wang F; Lu S; Yao S; Ke Z; Tai W; Jiang Y; Chen Y; Lu T
Mol Divers; 2012 Nov; 16(4):787-802. PubMed ID: 23090418
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
